Evidence map›Paper›PMID 31260374›Full record

ArticleJournal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research2019

Impact of

Vincent Pedergnana, William L Irving, Eleanor Barnes, John McLauchlan, Chris C A Spencer

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Variants ofGenes · 2023
    Article
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Vincent PedergnanaWellcome Centre Human Genetics, University of Oxford, Oxford, United Kingdom.
William L IrvingNational Institute for Health Research (NIHR) Nottingham Biomedical Research Centre, Nottingham University Hospitals NHS Trust and University of Nottingham, Nottingham, United Kingdom.
Eleanor BarnesNuffield Department of Medicine and the Oxford NIHR BRC, University of Oxford, Oxford, United Kingdom.
John McLauchlanCentre for Virus Research, MRC-University of Glasgow, Glasgow, United Kingdom.
Chris C A SpencerWellcome Centre Human Genetics, University of Oxford, Oxford, United Kingdom.

Funding

Department of Health 14/02/17Medical Research Council MC_UU_12014/1Medical Research Council MC_UU 12014/2Medical Research Council MR/K01532X/1Medical Research Council MR/N005953/1MRF_ C0365Wellcome TrustWellcome Trust 090532/Z/09/ZWellcome Trust 097364/Z/11/Z
6 · The paper itself

Abstract

Hepatitis C virus (HCV) genotype 3 is very prevalent in Europe and Asia and is associated with worst outcomes than other genotypes. Genetic factors have been associated with HCV infection; however, no extensive genome-wide study has been performed among HCV genotype 3 patients. In this study, using a large cohort of 1,759 patients infected with HCV genotype 3, we explore the role of genetic variants on the response to interferon (IFN) and direct-acting antiviral (DAA) regimens and viremia in a combined candidate gene and genome-wide analysis. We show that genetic variants within the IFN lambda 4 (

Indexed as

Genetic LociGenotypeHepacivirusInterleukinsPolymorphism, GeneticViremiaFemaleGenome-Wide Association StudyHumansInterferon LambdaMaleMiddle AgedRandomized Controlled Trials as TopicIFNL4 protein, humanInterferon LambdaInterleukinscandidate genesdirect-acting antiviralsgenome-wide association studyhepatitis C virusIFNL4

Identifiers

PMID31260374
PMCPMC6767867

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.